Brief: Candel Therapeutics Q2 Basic EPS USD -0.33
10/08/2023 13:11
Aug 10 (Reuters) - Candel Therapeutics Q2 operating expenses USD 9.579 million. * Q2 income from operations USD -9.579 million * Q2 net income USD -9.614 million * Q2 basic EPS USD -0.33
Recent news on Candel Therapeutics
See all newsBrief: Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints In Patients From Phase 3 Trial Of Aglatimagene Besadenovec (Can-2409)
Candel Therapeutics reports Q1 loss
Brief: Candel Therapeutics Q1 Net Income USD -8.861 Million
Brief: Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Candel Therapeutics Inc Extended Survival Tail Observed In Trial Of Aglatimagene Besadenovec